UPDATE: Piper Sandler Assumes Gossamer Bio Inc. (GOSS) at Overweight

September 21, 2021 4:00 AM EDT
Get Alerts GOSS Hot Sheet
Price: $14.07 +4.15%

Rating Summary:
    8 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 13 | Down: 13 | New: 72
Trade Now! 
Join SI Premium – FREE
(Updated - September 21, 2021 7:55 AM EDT)

Piper Sandler analyst Yasmeen Rahimi assumes coverage on Gossamer Bio Inc. (NASDAQ: GOSS) with an Overweight rating and a price target of $26.00.

The analyst commented, "We are assuming coverage of Gossamer Bio (GOSS), with an OW rating and $26 PT driven by strong conviction call on both clinical stage assets: Seralutinib, a triple action, inhaled PDGFRa/b, CSF1R, c-KIT inhibitor for pulmonary arterial hypertension (PAH) and GB004, an oral, gut-targeted HIF-1a stabilizer for ulcerative colitis (UC) with key binary data across two Phase 2b studies in 1H22 (24-week TORREY study in 80 PAH patients and 12-week Shift-UC in 195 UC patients). In our deep dive, we dug into the disease biologies, MOA, pre-clinical data, and clinical data from GOSS assets and approved compounds, giving us conviction that totality of data supports a high POS into TORREY and Shift-UC."

For an analyst ratings summary and ratings history on Gossamer Bio Inc. click here. For more ratings news on Gossamer Bio Inc. click here.

Shares of Gossamer Bio Inc. closed at $10.25 yesterday.

You May Also Be Interested In

Related Categories

Analyst Comments, New Coverage